391 related articles for article (PubMed ID: 22640909)
1. Nanoparticle delivery for transdermal HRT.
Valenzuela P; Simon JA
Nanomedicine; 2012 Sep; 8 Suppl 1():S83-9. PubMed ID: 22640909
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle delivery for transdermal HRT.
Valenzuela P; Simon JA
Maturitas; 2012 Sep; 73(1):74-80. PubMed ID: 22325243
[TBL] [Abstract][Full Text] [Related]
3. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
4. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
Baker VL
Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
[TBL] [Abstract][Full Text] [Related]
5. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Henzl MR; Loomba PK
J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
[TBL] [Abstract][Full Text] [Related]
6. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
[TBL] [Abstract][Full Text] [Related]
8. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
9. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
10. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
11. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
[TBL] [Abstract][Full Text] [Related]
12. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
13. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
14. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
Sajtos B; Herold J; Winkler UH; Schindler AE
Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
[TBL] [Abstract][Full Text] [Related]
16. Estrogen replacement therapy and the estraderm transdermal system.
Youngkin EQ
Nurse Pract; 1990 May; 15(5):19-26, 31. PubMed ID: 2342664
[TBL] [Abstract][Full Text] [Related]
17. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.
Balfour JA; Heel RC
Drugs; 1990 Oct; 40(4):561-82. PubMed ID: 2083514
[TBL] [Abstract][Full Text] [Related]
18. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women.
Castelo-Branco C; Coloma JL
Gynecol Endocrinol; 2010 Jan; 26(1):23-9. PubMed ID: 19639494
[TBL] [Abstract][Full Text] [Related]
19. Transdermal menopausal hormone therapy: delivery through skin changes the rules.
Buster JE
Expert Opin Pharmacother; 2010 Jun; 11(9):1489-99. PubMed ID: 20426703
[TBL] [Abstract][Full Text] [Related]
20. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
